Outlook Therapeutics Inc.

03/10/2026 | Press release | Distributed by Public on 03/10/2026 14:32

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders

At the Annual Meeting held on March 10, 2026, the Company's stockholders voted on three proposals, each of which is described in more detail in the Company's proxy statement on Schedule 14A filed with the Securities and Exchange Commission on January 26, 2026 (the "Proxy Statement"). Of the 73,509,455shares of the Company's common stock outstanding as of the record date, 37,271,431shares, or approximately 50.70%, were present or represented by proxy at the Annual Meeting.

The following is a brief description of each matter voted upon and the certified results, including the number of votes cast for and against each matter and, if applicable, the number of votes withheld, abstentions and broker non-votes with respect to each such matter.

Proposal 1.Stockholders elected each of the following nominees to serve as Class I directors on the Company's Board of Directors (the "Board") until the Company's 2029 Annual Meeting of Stockholders or until his successor has been duly elected and qualified. The voting results for such nominees were as follows:

Director Name Director Name Votes Against Votes Withheld Broker Non-
Votes
Yezan Haddadin 14,266,442 1,349,917 142,673 21,512,399
Faisal G. Sukhtian 14,192,499 1,161,669 404,864 21,512,399
Kurt J. Hilzinger 14,556,823 972,667 229,542 21,512,399

Proposal 2.Stockholders ratified the selection by the Audit Committee of the Board of KPMG LLP as the Company's independent registered public accounting firm for its fiscal year ending September 30, 2026. The voting results were as follows:

Votes For Votes Against Abstentions Broker Non-
Votes
35,628,284 751,849 891,298 0

Proposal 3.Stockholders approved a non-binding advisory vote on the compensation of the Company's named executive officers. The voting results were as follows:

Votes For Votes Against Abstentions Broker Non-
Votes
13,873,653 1,501,567 383,812 21,512,399
Outlook Therapeutics Inc. published this content on March 10, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on March 10, 2026 at 20:32 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]